Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

“Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynecological malignancies,” said Julie Eastland, Chief Executive Officer. “To support this goal, we have made the necessary decisions to efficiently organize our company and allocate our capital resources to extend cash runway beyond an anticipated azenosertib data readout that we believe has the potential to be registration-enabling. I want to thank all the individuals departing the Company for their valuable contributions to all Zentalis programs and the development of azenosertib. Tomorrow morning, we look forward to hosting a corporate event to share updated azenosertib clinical data and provide a development and regulatory update, including plans for our registration-intent studies, as we work to bring this therapeutic candidate forward to patients as quickly as possible.”